含砷剂方案治疗急性早幼粒细胞白血病的分析

Analysis on the treatment of acute promyelocytic leukemia with arsenic-containing agent regimen

目的回顾性分析急性早幼粒细胞白血病患者予以含砷剂及非砷剂方案的疗效及成本的差异。方法选择2012年12月~2016年12月桂林医学院附属医院初治的成人急性早幼粒细胞白血病患者27例,依据诱导方案不同分为观察组(12例)与对照组(15例),观察组予以含砷剂方案、对照组予以非砷剂方案,比较两组疗效及不良反应、成份血用量、诊疗费用的差异。结果两组完全缓解率,获得CR所需时间,2年总生存率,红细胞、血小板、血浆等用量及诊疗时长、诊疗费用等比较,差异均无统计学意义(均P>0.05)。结论急性早幼粒细胞白血病患者诱导治疗采用含砷剂方案与非砷剂方案的疗效和成本相似,仍需大样本量进一步研究。

Objective To retrospectively analyze the difference in clinical efficacy and cost between Arsenic-containing agent and non-arsenic-containing agent in patients with acute promyelocytic leukemia.Methods From December 2012 to December 2016,a total of 27 cases of adult acute promyelocytic leukemia patients primary treated in Affiliated Hospital of Guilin Medical University were selected.According to the different induction program,they were divided into observation group(12 cases)and control group(15 cases).The observation group was treated with arsenic-containing agent and the control group was treated with non-arsenic-containing agent.The differences of efficacy and adrerse reactions,blood dosage and medical expenses between the two groups were compared.Results There was no statistically significant difference between the two groups in the rates of complete remission,the time required to obtain CR,the 2-year overall survival rate,the dosage of red blood cells,platelets and plasma,the duration of treatment,and the cost of treatment(all P>0.05).Conclusion The efficacy and cost of induction therapy in patients with acute promyelocytic leukemia with arsenic-containing agent is similar to that with non-arsenic-containing agent,but it's necessary to study the large size sample further.